MIRXES-B (02629) has announced that all conditions have been fulfilled, and the settlement was completed on February 5, 2026. A total of 21.888 million placement shares were successfully allocated by the placing agent to no fewer than six independent placees at a price of HK$32.50 per share, in accordance with the terms and conditions of the placement agreement. Based on all reasonable inquiries made by the directors, the placees and their ultimate beneficial owners are independent third parties with no connections to the company or its related parties. The gross proceeds from the placement amounted to approximately HK$711 million. After deducting related costs, expenses, commissions, and fees, the net proceeds from the placement were approximately HK$673 million, representing a net price of about HK$30.77 per share. As previously disclosed, the net proceeds will be allocated as follows: (a) approximately 30% will be used for investment and merger and acquisition activities; (b) around 25% will be allocated to research and development, including clinical studies for existing pipelines and the development of new pipelines; (c) about 20% will be used for expansion into emerging markets; and (d) the remaining 25% will be allocated for general working capital purposes.